To view the Abstract, just click the link.
To request a reprint of the paper, click the link "Request Article", and send the Email
To download slides, right-click the link labeled "slides" and "Save Target As" to save the slides to your computer.
To return to the main library, just click "Back
PROVE IT - TIMI 22 Articles
1. Cannon CP, McCabe CH, Belder R, Breen J, Braunwald E. Design of the Pravastatin or Atorvastatin Evaluation and Infection Therapy (PROVE IT)-TIMI 22 trial. Am J Cardiol. 2002;89:860-1.
Abstract Request Article Slides
2. Cannon CP. PROVE-IT TIMI 22 Study: Potential effects on critical pathways for acute coronary syndrome. Crit Path Cardiol. 2003;2:188-196.
Abstract Request Article Slides
3. Gelfand EV, Cannon CP. Antibiotics for secondary prevention of coronary artery disease: an ACES hypothesis but we need to PROVE IT. Am Heart J. 2004;147:202-9.
Abstract Request Article Slides
Results
4. Cannon CP, Braunwald E, McCabe CH, Rader DJ, Rouleau J, Belder R, Joyal SV, Hill KA, Pfeffer M, Skene AM, for the Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 Investigators. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med. 2004;350:1495-1504.
Abstract Request Article Slides
5. Cannon CP, Braunwald E, McCabe CH, Grayston JT, Muhlestein B, Giugliano RP, Cairns R, Skene AM, for the Pravastatin or Atorvastatin Evaluation and Infection Therapy–Thrombolysis in Myocardial Infarction 22 Investigators. Antibiotic treatment of Chlamydia pneumoniae after acute coronary syndrome. N Engl J Med 2005;352:1646-54.
Abstract Request Article Slides
6. Ridker PM,Cannon CP, Morrow D, Rifai N, Ph.D., Lynda M. Rose LM, McCabe CH, Pfeffer MA, and Braunwald E, for the Pravastatin or Atorvastatin Evaluation and Infection Therapy–Thrombolysis in Myocardial Infarction 22 (PROVE IT–TIMI 22) Investigators Clinical Relevance of C-Reactive Protein Levels after Statin Therapy New England Journal of Medicine 352;1 January 6, 2005.
Abstract Request Article Slides
7. Ridker PM, Morrow DA, Rose LM, Rifai N, Cannon CP, Braunwald E. Relative efficacy of atorvastatin 80 mg and pravastatin 40mg in achieving the dual goals of LDL-C < 70 mg/dl and CRP <2 mg/L: An analysis of the PROVE-IT TIMI 22 Trial. J Am Coll Cardiol 2005; 45: 1644–8
Abstract Request Article Slides
8. Cannon CP, Braunwald E. Intensive versus Moderate Lipid Lowering with Statins after Acute Coronary Syndromes. N Engl J Med 2004;351:714-7.(letter)
Abstract Request Article Slides
9. Ridker PM, Cannon CP, Braunwald E. C-reactive protein levels and outcomes after statin therapy. N Engl J Med 2005;352:1603-05.(letter)
10. Grayston JT, Cannon CP. Antibiotic treatment of chlamydia pneumoniae after acute coronary syndrome. N Engl J Med 2005; 353 (5), 525-8 (letter)
11. Ray KK, Cannon CP, Cairns R, Tonkin AM, Sacks FM, Jackson G, McCabe C, Braunwald E. Early and Late Benefits of High-Dose Atorvastatin in Patients With ACS . A PROVE IT-TIMI 22 substudy. JACC 2005; 46 (8), 1405-1410
Abstract Request Article Slides
12. Ray KK, Cannon CP, Cairns R, Morrow DA, Kirtane AJ, McCabe CH, Gibson CM, Ridker PM, Braunwald E. Relationship between uncontrolled risk factors on C- reactive protein levels in patients receiving standard or intensive statin therapy for acute coronary syndromes in the PROVE IT-TIMI 22 Trial. JACC 2005; 46 (8), 1417-1424
Abstract Request Article Slides
13. Wiviott S, Cannon CP, Morrow D, Ray KK, Pfeffer M, Braunwald E. Can LDL be too low? The safety and efficacy of achieving very low LDL with intensive statin therapy: A PROVE IT - TIMI 22 substudy JACC 2005; 46 (8), 1411-1416
Abstract Request Article Slides
14. Reid IR, Tonkin A, Cannon CP. Comparison of the effects of pravastatin and atorvastatin on fracture incidence in the PROVE IT-TIMI 22 trial—secondary analysis of a randomized controlled trial. Bone. 2005;37(2):190-1.
15. Jocelyn Dupuis, MD, PhD, Jean-Claude Tardif, MD, Jean-Lucien Rouleau, MD, Joseph Ricci, MD, Malcolm Arnold, MD, Eva Lonn, MD, René Roux, MD, Lawrence M. Title, MD, Robert Amyot, MD, Nickie Bonafede, MD, Anna Woo, MD, and Christopher P. Cannon, MD Intensity of Lipid Lowering With Statins and Brachial Artery Vascular Endothelium Reactivity After Acute Coronary Syndromes (from the BRAVER Trial) (American Journal of Cardiology 2005;96:1207–1213)
Abstract Request Article Slides
16. Wiviott SD, de Lemos JA, Cannon CP, Blazing M, Murphy SA, McCabe CH, Califf R, Braunwald E. A tale of two trials: A comparison of the post-acute coronary syndrome lipid-lowering trials A to Z and PROVE IT-TIMI 22. Circulation. 2006;113(11):1406-
Abstract Request Article Slides
17. Benjamin M. Scirica, David A. Morrow, Christopher P. Cannon, Kausik K. Ray, Marc S. Sabatine, Petr Jarolim, Amy Shui, Carolyn H. McCabe, and Eugene Braunwald for the PROVE IT–TIMI 22 Investigators Intensive Statin Therapy and the Risk of Hospitalization for Heart Failure After an Acute Coronary Syndrome in the PROVE IT–TIMI 22 Study Journal American College of Cardiology June 6 2006;47: 2326 –31
Abstract Request Article Slides
18. O’Donoghue M, Morrow DA, Sabatine MS, Murphy SA, McCabe CH, Cannon CP, Braunwald E. Lipoprotein-Associated Phospholipase A2 and Its Association With Cardiovascular Outcomes in Patients With Acute Coronary Syndromes in the PROVE IT-TIMI 22 (PRavastatin Or atorVastatin Evaluation and Infection Therapy–Thrombolysis In Myocardial Infarction) Trial (Circulation. 2006 Apr 25; 105.612630)
Abstract Request Article Slides
19. Mega JL, Morrow DA, Cannon CP, Murphy S, Cairns R, Ridker PM, Braunwald E. Cholesterol, C-Reactive Protein, and cerebrocascular events following intensive and moderate statin therapy J Thromb Thrombolysis (2006 Aug) 22-71-76
Abstract Request Article Slides
20. Cannon CP, Steinberg BA, Murphy SA, Mega JL, Braunwald E. Meta-Analysis of Cardiovascular Outcomes Trials Comparing Intensive Versus Moderate Statin Therapy (J Am Coll Cardiol Aug 1 2006;48:438–45)
Abstract Request Article Slides
21. Ray KK, Bach RG, Cannon CP, Cairns R, Kirtane AJ, Wiviott SD, McCabe CH, Braunwald E, and Gibson CMfor the PROVE IT-TIMI 22 Investigators. Benefits of achieving the NCEP optional LDL-C goal among elderly patients with ACS. European Heart Journal August 3 2006
Abstract Request Article Slides
Review articles
22. Cannon CP. The next step in cardiovascular protection. Atherosclerosis. 2003;Suppl 4:3-9.
Abstract Request Article Slides
23. Ray KK, Cannon CP. Pathological changes in acute coronary syndromes: The role of statin therapy in the modulation of inflammation, endothelial function and coagulation. J Thromb Thrombolysis 2004;18:89-101.
Abstract Request Article Slides
24. Ray KK, Cannon CP. Intensive statin therapy in acute coronary syndromes: Clinical benefits and vascular biology. Curr Opin Lipid 2004:637-643.
Abstract Request Article Slides
25. Ray KK, Cannon CP. Time to benefit: An emerging concept for assessing the efficacy of statin therapy in cardiovascular disease. Critical Pathways in Cardiology 2005; 4: 43-45
Abstract Request Article Slides
26. Ray KK, Cannon CP. State of the art paper: The potential relevance of the multiple lipid independent (pleiotropic) effects of statins in the management of acute coronary syndromes. JACC 2005; 46 (8), 1425-1433
Abstract Request Article Slides
27. Ray KK, Cannon CP. Early Time to Benefit with Intensive Statin Treatment. Could it be the pleiotropic effects? American Journal of Cardiolog. 2005; 96 (5S), 54-60
Abstract Request Article Slides
28. Ray KK, Cannon CP. Atorvastatin and cardiovascular protection: A review and comparison of recent clinical trials. Expert Opinions in Pharmacotherapy 2005;6:915-927.
Abstract Request Article Slides
29. Ray KK, Cannon CP. Optimal goals for statin therapy in the management of CAD. Current Opinions in Cardiology 2006 In press
Abstracts (without published papers)
30. Giugliano R, Cannon CP, Rader DJ, Grundy SM, McCabe C, Braunwald E. Graded benefit of atorvastatin over pravastatin dependent upon baseline LDL. Circulation 2004;110 (Suppl. III):III-696.
31. Gibson CM, Sabatine MS, Murphy E, Morrow DA, Wiviott SD, Smith S, McCabe CH, Cannon CP, Braunwald E. Association of intensive lipid lowering with reductions in target vessel revascularization (clinical restenosis) and non-target vessel revascularization (lesion progression): A PROVE IT TIMI 22 Substudy. Circulation 2004;110 (Suppl III):696.
32. Sabatine MS, Wiviott SD, Morrow DA, McCabe CH, Cannon CP. High-dose atorvastatin asssociated with worse glycemic control: A PROVE-IT TIMI 22 Substudy. Circulation 2004;110 (Suppl III):834.
Abstract Request Article Slides
33. Ray KK, Morrow DA, Murphy S, McCabe C, Gibson CM, Cannon CP. Baseline urinary albumin concentration predicts long term cardiovascular risk in acute coronary syndrome patients: A PROVE IT-TIMI 22 Substudy. J Am Coll Cardiol 2005;45 (Suppl A):195A.
Abstract Request Article Slides
34. Bugiardini R, Manfrini O, Murphy SA, De Ferrari GM, Cannon CP. Long-term prognosis of non-obstructive coronary artery disease in the setting of acute coronary syndrome: A TIMI 22 Substudy. JACC 2005;45 (Suppl. A):208A.
35. Ray KK, Cannon CP, Cairns R, Wiviott SD, Kirtane AJ, Sabatine MS, McCabe CH, Braunwald E, Gibson CM. Beyond LDL Control: Additional benefits of better control of hypertension and glycemia in patients on statin therapy: An analysis from PROVE IT-TIMI 22. J Am Coll Cardiol 2005;45 (Suppl A):332A.
Abstract Request Article Slides
36. Wiviott SD, Cannon CP, Ray KK, Murphy S, Darius H, Castaigne A, Velasco JA, McCabe CH, Gibson CM. Seasonal variations in lipid values in patients following ACS: PROVE IT-TIMI 22. J Am Coll Cardiol 2005;45 (Suppl A):394A.
Abstract Request Article Slides
37. Wiviott SD, Cannon CP, Morrow DA, Scirica BM, McCabe CH, Braunwald E. Elevations in creatine kinase (CK) with intensive statin treatment: a PROVE IT-TIMI 22 substudy. J Am Coll Cardiol 2005;45 (Suppl A):413A.
38. Rose E, McCabe CH, Cairns R, Cannon CP, Braunwald E. Dramatic Benefit of intensive statin therapy in women: Results from PROVE IT - TIMI 22. J Am Coll Cardiol 2005;45 (Suppl A):12A.
Abstract Request Article Slides
39. Ray KK, Cannon CP, Rader DJ, Cairns R, McCabe CH, sacks FM, Braunwald E. Baseline ApoB predicts benefits of intensive statin therapy in patients with ACS: An analysis from PROVE IT-TIMI 22. Eur Heart J 2005; (26), 309
40. Ray KK, Cannon CP, Morrow DA, Cairns R, Braunwald E. Percutaneous coronary intervention for ACS is associated with a long-term reduction in CRP: An analysis from PROVE IT-TIMI 22. Eur Heart J. 2005; (26), 309
41. Ray, KK, Cannon CP, Gibson CM, Cairns R, Kirtane AJ, McCabe CH, Braunwald E. What are the future targets of therapy beyond intensive statin therapy? An analysis from PROVE IT-TIMI 22 Eur Heart J 2005; (26), 553
42. Ahmed S, Cannon CP, McCabe CH, Murphy SA, Braunwald E. Acute Coronary Syndromes and Diabetes Mellitus: Does Intensive Lipid Lowering Work? Eur Heart J 2005; (26),
43. Danik JS, Chasman DI, Cannon CP, Miller DT, Zee RY, Kozlowski P, Kwiatkowski D, Ridker PM. Influence of Genetic Variation in the C-Reactive Protein Gene on the Inflammatory Response During and After Acute Coronary Ischemia. Circulation. 2005;112(17):II-523
44. Ray KK, Cannon CP, Morrow DA, Cairns R, McCabe CH, Ridker PM, Braunwald E. CRP is additive and independent of ApoB/A1 ratio in explaining the clinical benefits of atorvastatin 80mg in ACS patients in PROVE IT-TIMI 22. Circ in press
45. Schweiger MJ, Giugliano RP, Lotfi A, Murphy SA, Cannon CP. High dose atorvastatin does not impact the efficacy of clopidogrel – A PROVE IT-TIMI 22 analysis. J Am Coll Cardiol. 2006: 47 (4): 380A.